Sanofi Pasteur Swiftwater PA delivers reliable influenza protection for adults and children in the Pennsylvania region. This cell-based quadrivalent vaccine combines established manufacturing with modern antigenic updates.
Designed to meet local public health needs, this vaccine aligns with current CDC guidance and is widely available across medical groups and retail pharmacies in Pennsylvania.
| Vaccine Platform | Antigen Match | Age Range | Dose Volume | Common Side Effects |
|---|---|---|---|---|
| Cell-based (MDCK) | 2024–2025 updated strains | 6 months + | 0.5 mL | Local soreness, low-grade fever |
| Egg-adapted adjustments | Minor egg residual protein | 6 months + | 0.5 mL | Similar to standard IIV |
| Storage | 2–8°C refrigerated | N/A | Liquid pre-filled | No frozen storage required |
| Pregnancy status | Recommended in any trimester | Adults included | Single dose | Compatible with other vaccines |
Manufacturing Standards at Sanofi Pasteur Swiftwater PA
The Swiftwater facility adheres to stringent U.S. and global quality standards, applying robust process controls and release testing.
Key Operational Controls
Batch consistency, sterility, and potency are validated through in-process checks and final lot release by both facility and regulatory authorities.
Clinical Effectiveness of Sanofi Pasteur Swiftwater PA
Real-world effectiveness data support cell-based influenza vaccines in reducing medically attended illness and hospitalizations across age groups.
Effectiveness Highlights
Studies indicate meaningful protection against matched circulating strains, with durability spanning the influenza season when vaccination occurs before local circulation peaks.
Access and Distribution in Pennsylvania
Sanofi Pasteur Swiftwater PA supplies clinics, health departments, and retail sites across the state, supporting broad access through public and private payers.
Availability Notes
Providers can order through standard channels; lead times vary seasonally, and contracts with group practices help ensure consistent local inventory.
Safety Profile and Contraindications
The most common local and systemic reactions are mild and transient, consistent with other inactivated influenza vaccines.
Situations to Avoid or Delay
Severe allergic reaction to a prior dose or any component, including residual egg protein, warrants discussion with a clinician before vaccination.
Public Health Recommendations and Next Steps
Aligning vaccination efforts with official guidance helps maximize community protection and reduce strain on local healthcare resources during peak influenza periods.
- Schedule annual vaccination before the start of local influenza transmission
- Prioritize high-risk groups such as older adults, young children, and individuals with chronic conditions
- Verify provider participation with your insurance plan to minimize out-of-pocket costs
- Stay informed about updated antigenic composition each season from public health authorities
FAQ
Reader questions
Is Sanofi Pasteur Swiftwater PA suitable for someone with an egg allergy?
People with a history of severe egg allergy should discuss vaccination with their clinician, who may choose to administer it in a setting equipped for managing allergic reactions, as the vaccine contains small amounts of egg protein.
How soon does protection begin after vaccination?
Antibody levels typically rise about two weeks after injection, so planning vaccination before local influenza activity increases offers the best timing for protection.
Can I get this vaccine if I am pregnant or breastfeeding?
Yes, inactivated influenza vaccines, including Sanofi Pasteur Swiftwater PA, are routinely recommended during any trimester of pregnancy and while breastfeeding to protect both the individual and the infant.
What should I do if I experience a severe reaction after vaccination?
Seek immediate medical care for serious symptoms such as difficulty breathing, swelling of the face or throat, or fainting, and report the event to your healthcare provider and local vaccine adverse event system.